Literature DB >> 11731803

The antimalarial and cytotoxic drug cryptolepine intercalates into DNA at cytosine-cytosine sites.

John N Lisgarten1, Miquel Coll, Jose Portugal, Colin W Wright, Juan Aymami.   

Abstract

Cryptolepine, a naturally occurring indoloquinoline alkaloid used as an antimalarial drug in Central and Western Africa, has been found to bind to DNA in a formerly unknown intercalation mode. Evidence from competition dialysis assays demonstrates that cryptolepine is able to bind CG-rich sequences containing nonalternating CC sites. Here we show that cryptolepine interacts with the CC sites of the DNA fragment d(CCTAGG)(2) in a base-stacking intercalation mode. This is the first DNA intercalator complex, from approximately 90 solved by X-ray crystallography, to bind a nonalternating (pyrimidine-pyrimidine) DNA sequence. The asymmetry of the drug induces a perfect stacking with the asymmetric site, allowing for the stability of the complex in the absence of hydrogen bonding interactions. The crystal structure of this antimalarial drug-DNA complex provides evidence for the first nonalternating intercalation and, as such, provides a basis for the design of new anticancer or antimalarial drugs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11731803     DOI: 10.1038/nsb729

Source DB:  PubMed          Journal:  Nat Struct Biol        ISSN: 1072-8368


  35 in total

1.  Unusual intercalation of acridin-9-ylthiourea into the 5'-GA/TC DNA base step from the minor groove: implications for the covalent DNA adduct profile of a novel platinum-intercalator conjugate.

Authors:  Hemanta Baruah; Ulrich Bierbach
Journal:  Nucleic Acids Res       Date:  2003-07-15       Impact factor: 16.971

2.  Structural studies on ligand-DNA systems: A robust approach in drug design.

Authors:  Surat Kumar; Prateek Pandya; Kumud Pandav; Surendra P Gupta; Arun Chopra
Journal:  J Biosci       Date:  2012-07       Impact factor: 1.826

3.  Mechanisms of small molecule-DNA interactions probed by single-molecule force spectroscopy.

Authors:  Ali A Almaqwashi; Thayaparan Paramanathan; Ioulia Rouzina; Mark C Williams
Journal:  Nucleic Acids Res       Date:  2016-04-16       Impact factor: 16.971

Review 4.  A review of the anticancer potential of the antimalarial herbal cryptolepis sanguinolenta and its major alkaloid cryptolepine.

Authors:  C Ansah; K B Mensah
Journal:  Ghana Med J       Date:  2013-09

5.  Antileishmanial activity of cryptolepine analogues and apoptotic effects of 2,7-dibromocryptolepine against Leishmania donovani promastigotes.

Authors:  Sudipta Hazra; Subhalakshmi Ghosh; Sukalyani Debnath; Scott Seville; Vijay Kumar Prajapati; Colin W Wright; Shyam Sundar; Banasri Hazra
Journal:  Parasitol Res       Date:  2012-07       Impact factor: 2.289

6.  Identification of 3-phenylaminoquinolinium and 3-phenylaminopyridinium salts as new agents against opportunistic fungal pathogens.

Authors:  Tryphon K Mazu; Jagan R Etukala; Xue Y Zhu; Melissa R Jacob; Shabana I Khan; Larry A Walker; Seth Y Ablordeppey
Journal:  Bioorg Med Chem       Date:  2010-11-05       Impact factor: 3.641

Review 7.  Indolo[3,2-b]quinolines: synthesis, biological evaluation and structure activity-relationships.

Authors:  Eyunni V K Suresh Kumar; Jagan R Etukala; Seth Y Ablordeppey
Journal:  Mini Rev Med Chem       Date:  2008-06       Impact factor: 3.862

8.  Quinoline alkaloids as intercalative topoisomerase inhibitors.

Authors:  Kendall G Byler; Chen Wang; William N Setzer
Journal:  J Mol Model       Date:  2009-05-08       Impact factor: 1.810

9.  Expedient one-pot synthesis of indolo[3,2-c]isoquinolines via a base-promoted N-alkylation/tandem cyclization.

Authors:  Huy H Nguyen; James C Fettinger; Makhluf J Haddadin; Mark J Kurth
Journal:  Tetrahedron Lett       Date:  2015-09-30       Impact factor: 2.415

10.  Genomewide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae.

Authors:  Marta Rojas; Colin W Wright; Benjamin Piña; José Portugal
Journal:  Antimicrob Agents Chemother       Date:  2008-08-18       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.